2-fold rise and 4-fold-rise in neutralization antibody titer;Neutralizing antibody titer at Day 1;Neutralizing antibody titer at Day 15 (post-booster injection);Neutralizing antibody titer at Day 1 (pre-booster injection);Neutralizing antibody titer at Day 36;Neutralizing antibody titer at Day 36 (Cohorts 1 and 2 Comparator Group);Neutralizing antibody titer fold-rise post-vaccination;Presence of adverse events of special interest;Presence of immediate adverse events;Presence of medically-attended adverse events;Presence of serious adverse events;Presence of solicited injection site or systemic reactions;Presence of unsolicited adverse events;Responders, as determined by neutralizing antibody titers at Day 36;Responders, as determined by neutralizing antibody titers at Day 36 (Cohorts 1 and 2 Comparator Group)

2-fold rise and 4-fold-rise in neutralization antibody titer;Neutralizing antibody titer at Day 1;Neutralizing antibody titer at Day 15 (post-booster injection);Neutralizing antibody titer at Day 1 (pre-booster injection);Neutralizing antibody titer at Day 36;Neutralizing antibody titer at Day 36 (Cohorts 1 and 2 Comparator Group);Neutralizing antibody titer fold-rise post-vaccination;Presence of adverse events of special interest;Presence of immediate adverse events;Presence of medically-attended adverse events;Presence of serious adverse events;Presence of solicited injection site or systemic reactions;Presence of unsolicited adverse events;Responders, as determined by neutralizing antibody titers at Day 36;Responders, as determined by neutralizing antibody titers at Day 36 (Cohorts 1 and 2 Comparator Group)

2-fold rise and 4-fold-rise in neutralization antibody titer;Neutralizing antibody titer at Day 1;Neutralizing antibody titer at Day 15 (post-booster injection);Neutralizing antibody titer at Day 1 (pre-booster injection);Neutralizing antibody titer at Day 36;Neutralizing antibody titer at Day 36 (Cohorts 1 and 2 Comparator Group and all Cohort 3 arms);Neutralizing antibody titer fold-rise post-vaccination;Presence of adverse events of special interest;Presence of immediate adverse events;Presence of medically-attended adverse events;Presence of serious adverse events;Presence of solicited injection site or systemic reactions;Presence of unsolicited adverse events;Responders, as determined by neutralizing antibody titers at Day 36;Responders, as determined by neutralizing antibody titers at Day 36 (Cohorts 1 and 2 Comparator Group and all Cohort 3 arms)

2-fold rise and 4-fold-rise in neutralization antibody titer;Neutralizing antibody titer at Day 1;Neutralizing antibody titer at Day 15 (post-booster injection);Neutralizing antibody titer at Day 1 (pre-booster injection);Neutralizing antibody titer at Day 36;Neutralizing antibody titer at Day 36 (Cohorts 1 and 2 Comparator Group and all Cohort 3 arms);Neutralizing antibody titer fold-rise post-vaccination;Presence of adverse events of special interest;Presence of immediate adverse events;Presence of medically-attended adverse events;Presence of serious adverse events;Presence of solicited injection site or systemic reactions;Presence of unsolicited adverse events;Responders, as determined by neutralizing antibody titers at Day 36;Responders, as determined by neutralizing antibody titers at Day 36 (Cohorts 1 and 2 Comparator Group and all Cohort 3 arms)

2-fold rise and 4-fold-rise in neutralization antibody titer;Neutralizing antibody titer at Day 1;Neutralizing antibody titer at Day 36;Neutralizing antibody titer fold-rise post-vaccination;Presence of adverse events of special interest;Presence of immediate adverse events;Presence of medically-attended adverse events;Presence of serious adverse events;Presence of solicited injection site or systemic reactions;Presence of unsolicited adverse events;Responders, as determined by neutralizing antibody titers at Day 36

2-fold rise and 4-fold-rise in neutralization antibody titer;Neutralizing antibody titer at Day 1;Neutralizing antibody titer at Day 36;Neutralizing antibody titer fold-rise post-vaccination;Presence of adverse events of special interest;Presence of immediate adverse events;Presence of medically-attended adverse events;Presence of serious adverse events;Presence of solicited injection site or systemic reactions;Presence of unsolicited adverse events;Responders, as determined by neutralizing antibody titers at Day 36